A King's College London-led team performed a genome-wide association study of kidney transplant donors and recipients.
Milwaukee, Wis.-based TAI Diagnostics is developing a PCR-based assay for cell-free DNA as a way to monitor the health of transplanted organs.
The firm said it expects fourth quarter revenues of $12.3 million to $12.5 million, a year-over-year increase of 13 percent to 15 percent.
Investigators characterized expression activity in kidney grafts from a group of transplant recipients who remained rejection-free without immunosuppression.
Though revenues from its non-invasive heart transplant rejection test AlloMap fell about 5 percent, CareDx is already being reimbursed by Medicare for its new AlloSure test.
At the recent IDWeek conference, company collaborators presented early validation data on a blood-based assay for cell-free microbial DNA.
The researchers plan to evaluate cfDNA and single cells isolated from the urine of patients who have had kidney transplants to identify signs of graft failure.
Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.
The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.
Researchers have used CRISPR to develop piglets that lack retroviruses, paving the way to use pig organs in human transplantation, the New York Times reports.
A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.
A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.
Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.
In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.